

Ref: FOI/GS/ID 8186

Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone, Kent

Email: mtw-tr.foiadmin@nhs.net

www.mtw.nhs.uk

ME16 9QQ

10 May 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Drug usage.

You asked:

How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs:

- 1. Aubagio (teriflunomide)
- 2. Avonex (interferon beta-1a)
- 3. Betaferon (interferon beta-1b)
- 4. Brabio (glatiramer acetate)
- 5. Copaxone (glatiramer acetate)
- 6. Extavia (beta interferon-1b)
- 7. Gilenya (fingolimod)
- 8. Lemtrada (alemtuzumab)
- 9. Kesimpta (ofatumumab)
- 10. Mavenclad (cladribine)
- 11. Mayzent (siponimod)
- 12. Ocrevus (ocrelizumab)
- 13. Plegridy (peginterferon beta-1a)
- 14. Ponvory (ponesimod)
- 15. Rebif (beta interferon-1a)
- 16. Tecfidera (dimethyl fumarate)
- 17. Tysabri (natalizumab)
- 18. Tysabri (natalizumab) pre-filled syringes ONLY
- 19. Vumerity (diroximel fumarate)
- 20. Zeposia (ozanimod)

Trust response:

Under Section 21 of the Act we are not required to provide information in response to a request if the information is already reasonably accessible to

you. The information you requested is available from the trust website using the following link/s: https://www.mtw.nhs.uk/freedom-of-information/recent-foiresponses/ the link should take you to the Data to Support FOI FAQ's page where you need to click on the Pharmacy dropdown. If the document does not open please copy and paste the link into your browser.

https://www.mtw.nhs.uk/wp-content/uploads/2023/04/April-2022-March-2023-Neurology-drugs-indication-by-quarter.xlsx

Alternatively, from our website home page, click the Freedom of Information Tab, then the Data to Support FOI FAQ's tab and then the Pharmacy dropdown at the bottom of the page where you will find all the information.

This information is updated on a regular basis and is exempt under Section 22 of the Act.